Tarsus Pharmaceuticals, Inc.

NasdaqGS:TARS Stok Raporu

Piyasa değeri: US$1.8b

Tarsus Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Tarsus Pharmaceuticals şirketinin toplam hissedar öz sermayesi $252.2M ve toplam borcu $71.6M olup, bu da borç-öz sermaye oranını 28.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $376.8M ve $124.6M dir.

Anahtar bilgiler

28.4%

Borç/özkaynak oranı

US$71.58m

Borç

Faiz karşılama oranın/a
NakitUS$323.58m
EşitlikUS$252.25m
Toplam yükümlülüklerUS$124.60m
Toplam varlıklarUS$376.84m

Son finansal sağlık güncellemeleri

Recent updates

Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41%

Nov 07
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41%

Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money

Nov 05
Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stocks Shoot Up 35% But Its P/S Still Looks Reasonable

Sep 05
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stocks Shoot Up 35% But Its P/S Still Looks Reasonable

Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment

Aug 20

With A 26% Price Drop For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) You'll Still Get What You Pay For

Jun 26
With A 26% Price Drop For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) You'll Still Get What You Pay For

Following Up On Tarsus Pharmaceuticals

May 28

Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results

May 11
Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results

Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name

Mar 08

Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic

Mar 03
Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 01
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?

Feb 28
Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?

New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Nov 12
New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates

Aug 16
What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: TARS 'nin kısa vadeli varlıkları ( $362.6M ) kısa vadeli yükümlülüklerini ( $51.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: TARS şirketinin kısa vadeli varlıkları ( $362.6M ) uzun vadeli yükümlülüklerini ( $73.0M ) aşmaktadır.


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: TARS şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: TARS şirketinin borç/öz sermaye oranı son 5 yılda 0.3% seviyesinden 28.4% seviyesine yükseldi.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: TARS şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: TARS serbest nakit akışı her yıl % 60.7 1.8 yıl yetecek nakit akışına sahip olacaktır.


Sağlıklı şirketleri keşfedin